HTAC recommendation for eribulin in the treatment of soft tissue sarcoma patients with previous treatment of two other chemotherapeutic agents for metastatic disease
HTAC recommendation for the non-inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma
Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-infection
HTAC recommendation on the minor inclusion of sambong 250mg tablet for anti-urolithiasis (kidney stones) in the Philippine National Formulary (PNF)
Tenofovir/Lamivudine/Dolutegravir (TLD) for treatment-naive and treatment-experienced adolescents and adults living with HIV
